Oral immunization with Lactococcus lactis-expressing EspB induces protective immune responses against Escherichia coli O157:H7 in a murine model of colonization by Ahmed Abdelrahman Mohamed, Bakr et al.
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Enterohemorrhagic  Escherichia  coli (EHEC)  have  been  responsible  for  several  outbreaks  of
hemolytic–uremic  syndrome  (HUS)  worldwide.  HUS  is  the most  common  cause  of  acute  renal  failure  in
children  and  results  in  fatalities  as high  as  50%  in  the  elderly.  Currently,  neither  a speciﬁc  treatment  nor  a
vaccine is  available  for EHEC.  Lactococcus  lactis is a generally  regarded  as  safe  “GRAS”  bacterium  that  offers
a  valuable  platform  for  oral  vaccine  delivery.  Toward  the  development  of an  oral  vaccine  against  EHEC,  we
have  previously  constructed  a recombinant  L.  lactis  strain  expressing  the EHEC  antigen,  EspB  in  the  cyto-
plasmic  compartment.  However,  oral  immunization  of mice  with  this  strain  induced  weak  priming  of the
immune  system.  This  outcome  was  attributed  to  the rather  low  levels  of  EspB  expressed  by this  recom-
binant  strain.  Therefore,  in  the present  study  we  optimized  the expression  of  EspB  in L.  lactis  by  secreting
the  antigen  either  under  constitutive  or nisin-inducible  control.  Indeed,  oral  immunization  of  mice  with
the EspB-secreting  strains  successfully  induced  speciﬁc  mucosal  and  systemic  antibody  responses.  These
responses  were  associated  with  mixed  Th1/Th2  cell  responses  in  Peyer’s  Patches  and  mesenteric  lymph
nodes.  Moreover,  immunized  mice  exhibited  signiﬁcant  protection  against  E.  coli  O157:H7  colonization,
as  indicated  by  the  reduced  amount  and/or  duration  of  the  bacterial  fecal  shedding.  Our results  demon-
strate  the  protective  potential  of EspB  as  an oral  vaccine  against  EHEC  infection.  Additionally,  the  study
demonstrates  the  efﬁcient  delivery  of  recombinant  EspB  by  the  “GRAS”  bacterium,  L. lactis.  The  safety
proﬁle  of  L.  lactis  as a vaccine  vehicle  can  particularly  be beneﬁcial  to children  and  elderly  as  high-risk
groups  for  HUS  incidence.
© 2014  Elsevier  Ltd. All  rights  reserved.. Introduction
Enterohemorrhagic Escherichia coli (EHEC) is one group of col-
nizing enteropathogens that has been responsible for frequent
utbreaks of diarrhea and hemorrhagic colitis (HC) worldwide [1].
C occasionally progresses to hemolytic–uremic syndrome (HUS),
hich is the most common cause of acute renal failure in chil-
ren [2] and results in fatality rates as high as 50% in the elderly
3]. HC and HUS are caused by shiga-like toxins (Stxs), which
re released by colonizing EHEC into the systemic circulation and
nduce endothelial damage in intestinal and renal vasculatures [4].
everal studies have linked antibiotic therapy to higher rates of
US development and prolonged duration of the symptomatic dis-
ase, probably due to the excessive release of Stxs upon bacterial
∗ Corresponding author. Tel.: +32 4 834 32240; fax: +32 9 264 7797.
E-mail address: Eric.Cox@UGent.be (E. Cox).
ttp://dx.doi.org/10.1016/j.vaccine.2014.05.054
264-410X/© 2014 Elsevier Ltd. All rights reserved.lysis [3,5–7]. Therefore, current disease intervention strategies are
rather focusing on vaccination. However, no vaccine is currently
available for EHEC infections.
Since the Stxs-mediated EHEC diseases develop subsequent to
the bacterial intestinal colonization, the latter is considered a key
determinant of EHEC pathogenicity and represents a potential tar-
get for vaccine design. EHEC colonizes the intestine with the aid
of a type III secretion system (T3SS) which enables the bacteria
to establish a tight adherence to enterocytes and to modify their
cytoskeletal proteins, leading to the characteristic attaching and
effacing lesion [8]. EspB is a T3SS protein that plays a central role in
mediating the EHEC enterocyte adherence [8–12]. Moreover, EspB
is highly immunogenic in human patients [13–15] and in infected or
vaccinated animals [13,16]. Therefore, EspB is a potential candidate
antigen for vaccination against EHEC.
Oral vaccination can be a particularly efﬁcient approach to
interfere with EHEC intestinal colonization, as it can effectively
induce local immune responses at the intestinal mucosa, and
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oncurrently elicit systemic immune responses [17]. Nevertheless,
ral vaccines are at the risk of being degraded by the harsh gas-
rointestinal conditions. Thus, vaccine delivery systems represent
 useful strategy to ensure the efﬁcient oral delivery of antigens
18,19]. One of the interesting oral antigen delivery systems is
ased on genetically modiﬁed lactic acid bacteria (LAB) that simul-
aneously express and deliver antigens to the intestinal mucosa
20,21]. LAB have been traditionally used in food industry and
re generally regarded as safe “GRAS” for human consumption.
herefore, they particularly offer a safe tool for the oral delivery
f vaccines. Lactococcus lactis is a model LAB that has been exten-
ively studied for oral vaccine delivery. Numerous bacterial, viral
nd parasitic antigens were expressed in L. lactis and the resul-
ant recombinant strains were capable of inducing speciﬁc mucosal
nd systemic immune responses in mice upon oral administration
for a recent review, [22]). We  have recently reported the constitu-
ive cytoplasmic expression of EspB in L. lactis [23]. However, oral
mmunization of mice using this recombinant strain induced weak
riming of the immune system. This outcome was attributed to the
ow levels of EspB expressed by this strain [23].
In the present study, we describe the optimized expression of
spB in L. lactis. Additionally, we describe the speciﬁc immune
esponses elicited in mice upon oral immunization with the recom-
inant strains and the protection conferred against a challenge
nfection with E. coli O157:H7.
. Materials and methods
.1. Bacteria, plasmids and culture conditions
A summary of the bacterial strains and plasmids used in this
tudy is shown in Table 1. L. lactis was grown at 30 ◦C in liquid M17
edium (Difco) supplemented with 0.5% glucose. Erythromycin or
hloramphenicol was added at concentrations of 5 and 10 g/ml,
espectively. E. coli NCTC12900 was grown at 37 ◦C in Luria–Bertani
roth (Difco) supplemented with 80, 15 and 100 g/ml of novo-
iocin, naladixic acid and streptomycin, respectively.
.2. Constructions of the EspB-expressing L. lactis strains
Plasmids pT:SEC-EspB and pNZ:SEC-EspB were constructed
or constitutive or nisin-inducible secretion of EspB, respec-
ively (Table 1 and Fig. 1). For construction of plasmid
T:SEC-EspB, the espB gene was PCR ampliﬁed from plasmid
T:CYT-EspB [23] using sequence-speciﬁc primer pairs (for-
ard: 5′-GGGGGATCCAACACTATCGATAACACTCAAG-3′; reverse:
′-GGGACTAGTTTAACCAGCAA GACG-3′). pT:CYT-EspB carries a
odon optimized espB gene of E. coli O157:H7 (Genbank Acces-
ion no: NC 002655), adapted to the preferential codon use
f L. lactis [23]. The ampliﬁed espB gene was inserted down-
tream of the secretion signal peptide SPUsp45 at the BamHI/SpeI
nds of pTREX1 (Fig. 1). For the construction of plasmid
NZ:SEC-EspB, espB along with SPUsp45 (SPUsp45–espB) was  PCR
mpliﬁed from pT:SEC-EspB using sequence-speciﬁc primer
airs (forward: 5′-ATGAAAAAAAAGATTATCTCAGC-3′; reverse: 5′-
GGACTAGTTTAACCAGCAAGACG-3′) and was inserted at the
caI/SpeI ends of plasmid pNZ8150 (Fig. 1). Plasmids pT:SEC-EspB
nd pNZ:SEC-EspB were used to transform electrocompetent L.
actis MG1363 and L. lactis NZ9000 [24] to obtain the recombi-
ant strains LL-pT:SEC-EspB and LL-pNZ:SEC-EspB, respectively
Table 1)..3. Induction and quantiﬁcation of EspB expression in L. lactis
Overnight cultures of the inducible LL-pNZ:SEC:EspB strain or
he constitutive, LL-pT:CYT:EspB and LL-pT:SEC:EspB strains were (2014) 3909–3916
inoculated in GM17 broth at dilutions of 1:25 and 1:100, respec-
tively. All strains were grown to an optical density at 600 nm of
0.4, at which, nisin (10 ng/ml) was added to the culture medium of
LL-pNZ:SEC:EspB. LL-pT:CYT:EspB and LL-pT:SEC:EspB cells were
harvested by centrifugation and resuspended in buffered-GM9
(BGM9) medium [25]. After a further 4 h incubation, cells or super-
natant of equal culture volumes were collected for each strain.
L. lactis cell lysates were enzymatically obtained as previously
described [23]. EspB was detected and quantiﬁed in cell lysates and
supernatants of the L. lactis cultures using a speciﬁc sandwich ELISA,
as previously described [23].
2.4. Oral immunization of mice with the EspB-expressing L. lactis
strains
Six-week-old female BALB/c mice were used in the animal
experiments. All experimental and animal management proce-
dures were approved by the animal care and ethics committee
of Ghent University, Belgium. The lactococcal strains were grown
and induced as described above. Cells of the inducible strains
were washed twice with sterile PBS to remove the traces of nisin.
Groups of nine mice were immunized orally with LL-pT:SEC:EspB,
LL-pNZ:SEC:EspB, puriﬁed EspB, LL-pTREX1, LL-pNZ8150 or the
inoculation medium BGM9 [25]. As a primary immunization mice
received 100 l of BGM9 containing 2 × 109 CFU of the proper lac-
tococcal strain or 5 g of puriﬁed EspB for three consecutive days. A
booster immunization was performed three weeks later using the
same regime.
2.5. EspB-speciﬁc antibodies
Total serum EspB-speciﬁc immunoglobulins (total-Ig) and faecal
IgA were measured 10 days after the booster immunization. Prepa-
ration of serum and fecal extracts as well as the ELISA procedures
were performed as previously described [23]. The ELISA results are
expressed as the OD values measured at 405 nm for dilutions of
1:10 for serum and 1:5 for fecal extracts.
2.6. Cytokine ELISA’s
Peyer’s patches (PP) and mesenteric lymph node (MLN) lym-
phocytes were isolated from immunized mice (n = 3), 10 days after
the booster immunization. Cells were resuspended at a concentra-
tion of 1.5 × 106 cells/ml in complete RPMI-1640 medium [26] and
cultured in 96-well plates. Cells were restimulated with EspB (ﬁnal
concentration: 10 g/ml) for 48 h. Thereafter, supernatants were
collected and assayed for murine INF-, IL-4 and IL-10 by quan-
titative ELISA using the mouse Th1/Th2 ELISA Ready-SET-Go® kit
(eBioscience), according to the manufacturer’s instructions.
2.7. Challenge with E. coli O157:H7
Groups of seven mice were immunized as described above. Ten
days after the booster immunization, mice of each group were ran-
domly divided into two  subgroups, of which, one subgroup (n = 4)
received streptomycin (5 g/l) in drinking water 24 h before infection
and till the end of the experiment, while the other subgroup (n = 3)
was not treated with streptomycin. These subgroups represent
two models of varying colonization intensities, since streptomycin
treatment enhances EHEC colonization in mice by clearing the com-
peting intestinal ﬂora [27]. Mice were challenged by intragastric
inoculation of 1010 CFU of E. coli NCTC12900 in 100 l of PBS con-
taining 20% sucrose. Faecal excretion of E. coli NCTC12900 was
monitored at 2–3 days interval, by both conventional bacterial plat-
ing and immuno-magnetic separation, as previously described [28].
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Table  1
Bacterial strains and plasmid vectors.
Plasmid or strain Description Reference
L. lactis subsp. cremoris MG1363 A derivative of the dairy starter strain NCDO712, which was  cured of all resident plasmids [61]
L. lactis NZ9000 L. lactis subspecies cremoris MG1363 carrying nisR and nisK genes on the chromosome [62]
LL-pTREX L. lactis subspecies cremoris MG1363 carrying plasmid pTREX [23]
LL-pNZ8150 L. lactis NZ9000 carrying plasmid pNZ8150 This study
LL-pT:SEC:EspB L. lactis subspecies cremoris MG1363 carrying plasmid pT:SEC:EspB This study
LL-pNZ:SEC:EspB L. lactis NZ9000 carrying plasmid pNZ:SEC:EspB This study
E.  coli NCTC12900 Shiga toxin-negative mutant of E. coli O157:H7, NovR, NalR and StrR [63]
pTREX1 L. lactis expression plasmid containing P1 promoter with downstream start codon and secretion signal (SPUsp45), EmR [46]
pNZ8150 L. lactis expression plasmid containing PnisA promoter with downstream start codon, CmR [64]
pT:CYT:EspB Modiﬁed pTREX1 containing P1 promoter with downstream espB gene, EmR [23]
pT:SEC:EspB Modiﬁed pTREX1 containing P1 promoter with downstream secretion signal (SPUsp45) and espB, EmR This study
r with R
N nicol a
2
s
(
F
w
c
apNZ:SEC:EspB Modiﬁed pNZ8150 containing PnisA promote
alR, StrR, CmR, EmR is resistance against naladixic acid, streptomycin, chloramphe
.8. Statistical analysesStatistical analyses were performed using GraphPad Prism 6
oftware (GraphPad Software Inc.). One-way analysis of variance
ANOVA) with Bonferroni post-hoc test was used to analyze the
ig. 1. Strategies for espB gene cloning in L. lactis. (A) The expression plasmid pTREX1 con
as  used for the insertion of the espB coding sequence between BamHI and SpeI restric
ontaining the nisin-inducible promoter PnisA was modiﬁed by inserting a fragment com
nd  SpeI restriction sites to form the plasmid pNZ:SEC:EspB. downstream secretion signal (SPUsp45) and espB, Cm This study
nd erythromycin, respectively.
differences in EspB expression levels among the strains as well as
the differences in antibody titers, cytokine ratios and duration of
fecal shedding among the groups. Pair-wise comparison of indi-
vidual cytokine levels among immunized and control groups were
analyzed using Student’s t-test. Two-way ANOVA with Bonferroni
taining the constitutive promoter P1 and the secretion peptide signal SP-Usps45
tion sites to form the plasmid pT:SEC:EspB. (B) The expression plasmid pNZ8150
bining the espB gene to an upstream secretion signal (SPUsp45-espB) between ScaI
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Fig. 2. Antibody responses in mice immunized with EspB-secreting lactococci.  Groups
of  mice (n = 9) were immunized using the constitutive strain LL-pT:SEC:EspB, the
inducible strain LL-pNZ:SEC:EspB or puriﬁed EspB. Corresponding control groups
were immunized using LL-pTREX1, LL-pNZ8150 or the oral inoculation medium,
BGM9. Ten days after the booster immunization serum and fecal samples were
assayed by ELISA for the presence of EspB-speciﬁc total-Ig (A) or IgA (B), respec-
tively. Data present individual values (triangles) and means (horizontal line) of nine912 B. Ahmed et al. / Vac
ost-hoc test was used to analyze the differences in fecal loads of
. coli NCTC12900 over time among the groups. Differences with a
 < 0.05 were considered statistically signiﬁcant.
. Results
.1. ELISA quantiﬁcation of EspB expression by the recombinant L.
actis strains
EspB was detected only in the cell lysate of LL-pT:CYT:EspB,
hile it was detected in both cell lysates and supernatants of LL-
NZ:SEC:EspB and LL-pT:SEC:EspB (Table 2). The detection of EspB
n cell lysates of the EspB-secreting strains corresponds to the pres-
nce of the cytoplasmic precursor of the mature (secreted) protein.
he total amount of EspB expressed by the secreting strains LL-
NZ:SEC:EspB and LL-pT:SEC:EspB (both cytoplasmic and secreted)
as, respectively, 56- and 25-fold higher than that expressed by
he cytoplasmic expression strain LL-pT:CYT:EspB (P < 0.05). The
isin-inducible LL-pNZ:SEC:EspB strain showed a 2.2-fold higher
otal EspB expression than the constitutive LL-pT:SEC:EspB strain
P < 0.05) (Table 2). Both LL-pNZ:SEC:EspB and LL-pT:SEC:EspB
ere used for the immunization experiments.
.2. EspB-secreting L. lactis strains induce speciﬁc antibody
esponses after oral administration to mice
Mice orally immunized with either LL-pNZ:SEC:EspB or LL-
T:SEC:EspB showed signiﬁcantly higher levels of EspB-speciﬁc
erum total-Ig (P < 0.0001) and faecal IgA (P < 0.0001) compared
o those immunized with the corresponding control strains,
L-pNZ8150 and LL-pTREX1, respectively (Fig. 2). The highest
ntibody responses were elicited by the nisin-inducible strain LL-
NZ:SEC:EspB compared to the constitutive strain LL-pT:SEC:EspB
P < 0.0001). Mice immunized with puriﬁed EspB showed no signif-
cant difference in total serum Ig and faecal IgA compared to those
eceiving the BGM9 medium.
.3. Oral immunization with L. lactis-secreting EspB induces
ixed Th1/Th2 immune response
To characterize the cellular immune responses induced by the
ral immunization with the EspB-secreting L. lactis strains, the
roduction of INF- (Th1 cytokine), IL-4 (Th2 cytokine) [29] and
L-10 (a broadly expressed anti-inﬂammatory cytokine) [29,30]
as measured in PP (Fig. 3A) and MLN  (Fig. 3C) lymphocytes
fter in vitro restimulation with EspB. Lymphocytes of both
L-pT:SEC:EspB and LL-pNZ:SEC:EspB immunized mice showed
 signiﬁcant higher production of all cytokines compared to
hose immunized with LL-pTREX1 and LL-pNZ8150, respectively
P < 0.0001). This ﬁnding indicates a mixed Th1/Th2 cell response.
ice immunized with puriﬁed EspB showed no signiﬁcant increase
n cytokine production compared to those received the BGM9
edium.
To determine the Th1/Th2 cell-type dominance, the IL-4/INF-
atio was further analyzed for PP (Fig. 3B) and MLN  (Fig. 3D) lym-
hocytes. The ratio in both LL-pNZ:SEC:EspB and LL-pT:SEC:EspB
mmunized mice was greater than one and was signiﬁcantly higher
han the baseline ratios shown by control mice immunized with
he respective empty vector strain or with the BGM9 medium. This
nding indicates a dominance of the Th2 response.
.4. Oral immunization with L. lactis-secreting EspB protects
ice against E. coli O157:H7 colonization
Comparisons of E. coli O157:H7 fecal counts among the immu-
ization groups within either streptomycin-treated (Fig. 4A) ormice per group. Statistical differences were determined using one-way ANOVA with
Bonferroni post-hoc test (* P < 0.0001; NS = non signiﬁcant difference).
non-streptomycin-treated (Fig. 4B) challenge groups show signif-
icantly reduced counts in LL-pNZ:SEC:EspB and LL-pT:SEC:EspB
groups in comparison to LL-pNZ8150 and LL-pTREX1 groups,
respectively, or to the BGM9 group, at most of the time
points (P < 0.05). This reduction was  signiﬁcantly higher in
the LL-pNZ:SEC:EspB immunization group compared to the LL-
pT:SEC:EspB group (P < 0.05) (Fig. 4A and B).
Additionally, comparisons of the durations of E. coli O157:H7
fecal shedding among the streptomycin-treated immuniza-
tion groups show a signiﬁcantly shorter duration in the LL-
pNZ:SEC:EspB group (11.52 ± 2.87 days) compared to LL-pNZ8150
and BGM9 groups (30.5 ± 1.73 and 29.75 ± 1.5 days, respectively)
(P < 0.05). However, the duration of fecal shedding shown by the
LL-pT:SEC:EspB group was not signiﬁcantly shorter than that of the
LL-pTREX1 or the BGM9 group (26.75 ± 1.5 days versus 29.75 ± 1.5
days). Within the non-streptomycin-treated immunization groups,
the duration of fecal shedding shown by the LL-pNZ:SEC:EspB
group (11.52 ± 2.87 days) and the LL-pT:SEC:EspB group (16 ± 1.73
days) was signiﬁcantly shorter than that of the LL-pNZ8150 group
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Table  2
ELISA quantiﬁcation of EspB production by the recombinant L. lactis strains.
Strain Expression features EspB expression in fractions of cultures (g/ml)†
Cell lysate Supernatant Total
LL-pNZ:CYT:EspB Nisin-inducible cytoplasmic 0.082 ± 0.02 ND* 0.082 ± 0.02a
LL-pNZ:SEC:EspB Nisin-inducible secretion 0.83 ± 0.19 3.8 ± 1.1 4.63 ± 1.29a
LL-pT:SEC:EspB Constitutive secretion 0.15 ± 0.05 1.9 ± 0.4 2.05 ± 0.45a
 stand
i pos
(
o
d
c
4
s
F
L
f
L
t
i
o† Culture density approximately equal to 8 × 108 CFU/ml. Data represent means ±
a Signiﬁcant differences among the strains using one way-ANOVA with Bonferron
* ND: non detectable.
19.3 ± 2.31 days) and the LL-pTREX1 group (22 days), respectively
r than that of the BGM9 group (22 days) (P < 0.05). The shorter
uration of fecal shedding shown by the LL-pNZ:SEC:EspB group in
omparison to the LL-pT:SEC:EspB group was signiﬁcant (P < 0.05).. Discussion
We  have recently reported the constitutive cytoplasmic expres-
ion of EspB in L. lactis (LL-pT:CYT:EspB) [23]. However, oral
ig. 3. Cytokine responses of Peyer’s patches (PP) (A and B) and mesenteric lymph nodes
.  lactis. Ten days after the booster immunization, lymphocytes were isolated from PP a
or  production of IFN-, IL-4 and IL-10 cytokines. Data present the mean ± SD. Asterisks 
L-pNZ:SEC:EspB and EspB compared to the control groups LL-pTREX1, LL-pNZ8150 and B
-test  (P < 0.05). IL-4/INF- ratios were calculated to determine the dominant T-helper re
ndicate signiﬁcant difference between the immunization groups LL-pT:SEC:EspB and LL-pN
r  to the BMG9 control group (P < 0.05). Statistical differences were determined using oneard deviation of three independent measurements.
t-hoc test (P < 0.05).
vaccination of BALB/c mice with this strain induced a weak prim-
ing the immune system [23]. This outcome was attributed to the
low amount of EspB expressed by LL-pT:CYT:EspB, presumably due
to the antigen degradation by the lactococcal cytoplasmic pro-
teases [31–33]. Therefore, in the present study we hypothesized
that secretion could allow EspB to escape cytoplasmic proteolysis
and thus would result in a higher expression yield. Addition-
ally, we  compared a nisin-inducible and a constitutive expression
system for the highest protein expression. In accordance with
 (MLN) (C) and (D) lymphocytes from mice orally immunized with EspB-secreting
nd MLN of mice (n = 3) of immunized mice; restimulated with EspB, and assayed
indicate signiﬁcant difference between the immunization groups LL-pT:SEC:EspB,
GM9, respectively (P < 0.05). Statistical differences were determined using Student’s
sponse in PP (B) and MLN  lymphocytes (D). Data present the mean ± SD. Asterisks
Z:SEC:EspB compared to the respective control groups LL-pTREX1 and LL-pNZ8150,
-way ANOVA with Bonferroni post-hoc test (P < 0.05).
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Fig. 4. Kinetics of fecal shedding of E. coli O157:H7 in mice immunized orally with EspB
secreting lactococci. Ten days after the booster immunization, groups of immunized
mice were orally challenged with 1010 CFU of E. coli NCTC12900 (a non-toxigenic
mutant of E. coli O157:H7), either under oral streptomycin treatment condi-
tion (n = 4) (A) or without streptomycin treatment (n = 3) (B). Data present the
mean ± SD. Data points in rectangles indicate a signiﬁcant difference between the
LL-pT:SEC:EspB and pNZ:SEC:EspB immunization groups compared to the respec-
tive  control groups LL-pTREX1 and LL-pNZ8150 or to the BGM9 control group
(P  < 0.05). Asterisks indicate statistical differences between the LL-pT:SEC:EspB
a
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dnd LL-pNZ:SEC:EspB immunization groups (P < 0.05). Data present the mean ± SD.
tatistical differences were determined using two-way ANOVA with Bonferroni
ost-hoc test (P < 0.05).
ur hypothesis, secretion of EspB either under constitutive (LL-
T:SEC:EspB) or inducible (LL-pNZ:SEC:EspB) conditions resulted
n a great enhancement of the total antigen yield compared to
he cytoplasmic expression by LL-pT:CYT:EspB (56- and 25-fold
ncrease, respectively). A similar enhancement of the total pro-
ein yield by secretion in comparison to cytoplasmic expression
as been reported for the expression of the staphylococcal nucle-
se [34] and the Brucella abortus ribosomal protein L7/L12 [35] in
. lactis.
The immune response induced by the EspB-secreting lacto-
occi is expected to be inﬂuenced by EspB expression levels, which
re at least two times higher for the nisin-inducible strain, LL-
NZ:SEC:EspB compared to the constitutive strain, LL-pT:SEC:EspB.
n the other hand, LL-pT:SEC:EspB is capable of constant secre-
ion of EspB during the intestinal passage, which may  compensate
or the higher expression levels of LL-pNZ:SEC:EspB, whereas LL-
NZ:SEC:EspB may  not continue EspB secretion along the entire
uration of its intestinal passage as nisin is absent in vivo. How-
ver, the highest immune responses were obtained by the inducible
L-pNZ:SEC:EspB strain. In this regard, previous reports have
emonstrated the ability of nisin-inducible expression systems to (2014) 3909–3916
continue protein expression for at least 10 h after removal of nisin
from the culture medium [34]. Additionally, considering that the
reported transit time of L. lactis throughout the mouse gastroin-
testinal tract is approximately 12 h [36], it is highly likely that
both strains had a comparable persistence of EspB secretion in
vivo, while the higher responses induced by LL-pNZ:SEC:EspB are
a direct result of its higher capacity for EspB expression.
Unlike the mice immunized with the EspB-expressing L. lactis
strains, those immunized with puriﬁed EspB did not show speciﬁc
immune responses, even though EspB was  given at a dose approx-
imately equal to that present in the inoculum of LL-pT:SEC:EspB
(5 g). This ﬁnding could be explained by the ability of L. lactis
to maintain metabolic activity [37–39] and de novo secretion of
recombinant proteins [38,39] during its gastrointestinal passage,
leading to the delivery of higher amounts of EspB than those mea-
sured in the administered inocula [40]. Additionally, puriﬁed EspB
could have been inﬂuenced by the degrading effects of the gastroin-
testinal acidity and enzymes, a bottleneck that can be overcome
by using L. lactis as an antigen delivery vector. Moreover, L. lac-
tis exhibits adjuvant effects [41], which can enhance the immune
response to recombinant EspB in comparison to the puriﬁed protein
[42–44]. These arguments support the pharmacological and the
immunological value of L. lactis as an oral antigen delivery system
[45–47].
To characterize the cellular immune responses induced by oral
immunization of mice with the EspB-secreting strains, we  isolated
lymphocytes from PP and MLN, the main inductive sites of the gut
mucosal immune system [48] and measured the production of INF-
 (Th1 cytokine) and IL-4 (Th2 cytokine) [29]after stimulating the
cells with EspB in vitro. Both cytokines were produced by lym-
phocytes of immunized mice, indicating the induction of a mixed
Th1/Th2 cell response. Previous reports have similarly described a
mixed Th1/Th2 cell response to antigens orally delivered by L. lactis
[46,49,50]. Additionally, analysis of the IL-4:INF- ratio’s indicated
a dominance of the Th2 response, which is a typical characteristic
of an intestinal mucosal response [29,46]. The Th2 dominance cor-
responds well with the induced mucosal IgA responses, since Th2
cells and cytokines are known to contribute to mucosal IgA class
switching in PP and MLN  [51,52].
Reduced intestinal colonization is considered an important cri-
terion for protection against EHEC virulence [53,54]. Our ﬁndings
show that oral immunization of mice with the EspB-secreting L.
lactis strains resulted in a reduction of E. coli O157:H7 fecal shed-
ding. Moreover, the reduced bacterial shedding was consistent in
two infection models of varying colonization intensities indicating
the efﬁcacy and the reproducibility of our vaccination approach.
This pattern of protection could be correlated with an intestinal
EspB-speciﬁc IgA response, which is consistent with the protective
role of secretory IgA in mucosal infections [18]. However, previous
immunization studies in mice models, particularly those involv-
ing T3SS antigens, lack consensus on the necessity of intestinal
IgA responses for clearing an EHEC infection (recently reviewed
in [55]). For instance, intramuscular immunization with a mixture
of T3SS proteins eliminated EHEC shedding, despite the absence of
fecal Tir- or EspA-speciﬁc IgA responses [56]. On the other hand, a
subcutaneous immunization with Tir failed to induce intestinal IgA
responses and to protect mice against a challenge [57]. With regard
to EspB, previous reports have described the protective effect of
parenteral vaccination with formulations containing EspB [58,59].
However, these studies were performed in cattle, a species in which
IgG responses contribute largely to intestinal mucosal protection
[60]. The present study, however, is the ﬁrst to describe the protec-
tive potential of EspB upon oral vaccination.
In conclusion, oral immunization of mice with recombinant
L. lactis secreting EspB induces speciﬁc mucosal and systemic
immune responses and confers protection against an E. coli
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157:H7 challenge infection. These ﬁndings demonstrate the fea-
ibility of an oral vaccine based on the recombinant expression of
spB in L. lactis to control EHEC infection. The safety proﬁle of L.
actis as a vaccine delivery vector can particularly be beneﬁcial to
hildren and elderly, the high-risk groups for HUS complications
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